Altimmune Other Current Assets vs Current Deferred Revenue Analysis
ALT Stock | USD 7.26 0.06 0.83% |
Altimmune financial indicator trend analysis is way more than just evaluating Altimmune prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Altimmune is a good investment. Please check the relationship between Altimmune Other Current Assets and its Current Deferred Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altimmune. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Altimmune Stock please use our How to Invest in Altimmune guide.
Other Current Assets vs Current Deferred Revenue
Other Current Assets vs Current Deferred Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Altimmune Other Current Assets account and Current Deferred Revenue. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Altimmune's Other Current Assets and Current Deferred Revenue is 0.96. Overlapping area represents the amount of variation of Other Current Assets that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Altimmune, assuming nothing else is changed. The correlation between historical values of Altimmune's Other Current Assets and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Assets of Altimmune are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Other Current Assets i.e., Altimmune's Other Current Assets and Current Deferred Revenue go up and down completely randomly.
Correlation Coefficient | 0.96 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Other Current Assets
Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Most indicators from Altimmune's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Altimmune current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altimmune. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Altimmune Stock please use our How to Invest in Altimmune guide.At this time, Altimmune's Tax Provision is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 44.70 in 2024, despite the fact that Enterprise Value Over EBITDA is likely to grow to (5.31).
2021 | 2022 | 2023 | 2024 (projected) | Research Development | 74.5M | 70.5M | 65.3M | 68.6M | Depreciation And Amortization | 11.2M | 2.8M | 477K | 453.2K |
Altimmune fundamental ratios Correlations
Click cells to compare fundamentals
Altimmune Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Altimmune fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 54.1M | 245.1M | 218.9M | 206.9M | 210.6M | 221.2M | |
Other Current Liab | 3.6M | 11.0M | 6.1M | 11.8M | 9.6M | 17.1M | |
Total Current Liabilities | 3.9M | 12.0M | 18.3M | 17.1M | 12.1M | 21.2M | |
Total Stockholder Equity | 45.5M | 225.9M | 199.1M | 185.3M | 194.1M | 203.8M | |
Net Debt | (7.2M) | (114.1M) | (188.8M) | (110.0M) | (134.5M) | (127.8M) | |
Retained Earnings | (137.4M) | (186.4M) | (293.2M) | (377.9M) | (466.3M) | (443.0M) | |
Accounts Payable | 18.2K | 612.3K | 2.0M | 4.8M | 2.1M | 1.5M | |
Cash | 9.0M | 115.9M | 190.3M | 111.1M | 135.2M | 141.9M | |
Cash And Short Term Investments | 37.2M | 215.9M | 190.3M | 184.9M | 197.9M | 207.7M | |
Common Stock Total Equity | 876.0 | 1.5K | 3.7K | 4.1K | 4.7K | 3.9K | |
Common Stock Shares Outstanding | 13.1M | 25.6M | 41.3M | 46.9M | 53.2M | 55.9M | |
Liabilities And Stockholders Equity | 54.1M | 245.1M | 218.9M | 206.9M | 210.6M | 221.2M | |
Other Current Assets | 504.4M | 2.0B | 13.4B | 5.4M | 6.8M | 6.5M | |
Other Stockholder Equity | 187.9M | 417.3M | 497.3M | 568.4M | 665.4M | 698.7M | |
Total Liab | 8.5M | 19.2M | 19.7M | 21.6M | 16.5M | 27.3M | |
Total Current Assets | 39.4M | 230.3M | 204.1M | 192.8M | 209.5M | 220.0M | |
Common Stock | 1.5K | 3.7K | 4.1K | 5K | 7K | 4.2K | |
Other Assets | 128.5K | 977.2K | 73.8K | 19K | 1.0 | 0.95 | |
Non Current Liabilities Total | 4.6M | 7.2M | 1.5M | 4.6M | 4.4M | 4.7M | |
Short Term Debt | 259.4K | 356.7K | 411.5K | 452K | 496K | 471.2K | |
Short Long Term Debt Total | 1.7M | 1.8M | 1.5M | 1.1M | 671K | 637.5K | |
Property Plant And Equipment Net | 1.8M | 2.0M | 1.4M | 1.1M | 1.0M | 1.5M | |
Non Current Assets Total | 14.7M | 14.9M | 14.7M | 14.1M | 1.1M | 1.1M | |
Non Currrent Assets Other | 128.5K | 73.4K | 872.0K | 615K | 100.0K | 95.0K | |
Net Receivables | 1.7M | 12.4M | 5.8M | 2.5M | 4.9M | 5.0M | |
Property Plant And Equipment Gross | 1.8M | 2.0M | 1.4M | 2.6M | 2.6M | 1.6M | |
Accumulated Other Comprehensive Income | (5.0M) | (5.0M) | (5.0M) | (5.2M) | (5.0M) | (4.8M) | |
Intangible Assets | 12.7M | 12.8M | 12.4M | 12.4M | 14.3M | 11.8M | |
Net Tangible Assets | 32.8M | 213.1M | 186.7M | 172.9M | 198.8M | 208.7M | |
Long Term Debt | 1.9M | 1.9M | 1.8M | 1.5M | 1.7M | 1.5M | |
Retained Earnings Total Equity | (116.9M) | (137.4M) | (186.4M) | (293.2M) | (337.1M) | (354.0M) | |
Capital Surpluse | 170.2M | 187.9M | 417.3M | 497.3M | 571.9M | 600.5M | |
Property Plant Equipment | 1.1M | 1.1M | 1.4M | 1.7M | 1.9M | 2.0M | |
Long Term Debt Total | 1.9M | 1.9M | 1.8M | 1.5M | 1.7M | 2.0M | |
Non Current Liabilities Other | 2.8M | 5.4M | 1.5M | 3.9M | 4.2M | 4.4M | |
Other Liab | 3.1M | 7.2M | 330.5K | 3.9M | 4.5M | 3.3M |
Altimmune Implied Volatility | 623.6 |
Altimmune's implied volatility exposes the market's sentiment of Altimmune stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Altimmune's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Altimmune stock will not fluctuate a lot when Altimmune's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Altimmune in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Altimmune's short interest history, or implied volatility extrapolated from Altimmune options trading.
Pair Trading with Altimmune
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Altimmune position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Altimmune will appreciate offsetting losses from the drop in the long position's value.Moving against Altimmune Stock
0.68 | ACB | Aurora Cannabis Sell-off Trend | PairCorr |
0.56 | ELYM | Eliem Therapeutics Upward Rally | PairCorr |
0.56 | CGC | Canopy Growth Corp Financial Report 27th of June 2024 | PairCorr |
The ability to find closely correlated positions to Altimmune could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Altimmune when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Altimmune - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Altimmune to buy it.
The correlation of Altimmune is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Altimmune moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Altimmune moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Altimmune can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altimmune. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Altimmune Stock please use our How to Invest in Altimmune guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Complementary Tools for Altimmune Stock analysis
When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance |
Is Altimmune's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altimmune. If investors know Altimmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altimmune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.66) | Revenue Per Share 0.008 | Quarterly Revenue Growth 180 | Return On Assets (0.25) | Return On Equity (0.47) |
The market value of Altimmune is measured differently than its book value, which is the value of Altimmune that is recorded on the company's balance sheet. Investors also form their own opinion of Altimmune's value that differs from its market value or its book value, called intrinsic value, which is Altimmune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altimmune's market value can be influenced by many factors that don't directly affect Altimmune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Altimmune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Altimmune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altimmune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.